About Leiutis
Leiutis is a Healthcare company based in Hyderabad (India) founded in 2012. Pharmaceutical innovation company developing nanotherapeutics for global therapeutic areas. It operates on a B2B model. The company has 66 employees. Its Indian entity Leiutis Pharmaceuticals Llp reported revenue of ₹52.13 Cr. Leiutis offers products and services including Nanotherapeutics for Pain Management, Nanotherapeutics for Supportive Care, Nanotherapeutics for CNS Disorders, and Nanotherapeutics for Immunomodulators. Its focus areas include Pharmaceuticals, Nanotherapeutics, Supportive Care and Pain Management.
Company details
Leiutis is a pharmaceutical product innovation company specializing in nanotherapeutics to foster patient wellbeing through research and global partnerships. They focus on commercializing products in areas like pain management, supportive care, CNS disorders, and immunomodulators. Operating from Hyderabad, India, they engage in alliance partnerships for successful commercialization, emphasizing innovative treatments without promotional claims.
- Headquarters Hyderabad, India
- Employees 66
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website leiutis.com
- Social X Facebook
- Legal Name Leiutis Pharmaceuticals Llp
- Date of Incorporation 17 May, 2021
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹52.13 Cr
FY 2025 · -39% YoY
- Net Profit₹16.73 Cr
FY 2025 · 32% margin
- EBITDA₹28.53 Cr
FY 2025 · 55% margin
- Employee Count66
Associated legal entities of Leiutis
Leiutis operates through Leiutis Pharmaceuticals Llp (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Leiutis Pharmaceuticals Llp CIN AAX-0501 | Active | 17 May 2021 | Hyderabad, Telangana | ₹52.1 Cr | 72 | 6 | View details |
Products & Services of Leiutis
Leiutis offers a comprehensive portfolio of products and services, including Nanotherapeutics for Pain Management, Nanotherapeutics for Supportive Care, Nanotherapeutics for CNS Disorders, and Nanotherapeutics for Immunomodulators.
Innovative nanotechnology-based solutions for effective pain relief.
Treatments aiding patient support in various health conditions.
Advanced therapies targeting central nervous system issues.
Products modulating immune responses for therapeutic benefits.
Board of directors of Leiutis Pharmaceuticals Llp (Leiutis)
Leiutis Pharmaceuticals Llp is the primary company behind Leiutis. The board of Leiutis Pharmaceuticals Llp currently have 6 directors; the longest-serving is Manikreddy Pullagurla, appointed in 2021. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manikreddy Pullagurla DIN 01850939 | Designated Partner | 17 May 2021 | 5 yrs 5 mo | Leiutis Pharmaceuticals Llp |
| Harcharan Singh DIN 02852915 | Designated Partner | 17 May 2021 | 5 yrs 5 mo | Leiutis Pharmaceuticals Llp |
| Chandra Shekhar Kocherlakota DIN 05144398 | Designated Partner | 17 May 2021 | 5 yrs 5 mo | Leiutis Pharmaceuticals Llp |
| Ramprasad Nimmagadda DIN 05182046 | Designated Partner | 17 May 2021 | 5 yrs 5 mo | Leiutis Pharmaceuticals Llp |
| Madhusudana Rao Kothapalli DIN 00278238 | Designated Partner | 17 May 2021 | 5 yrs 5 mo | Leiutis Pharmaceuticals Llp |
| Jagadeesh Babu Rangisetty DIN 01725762 | Designated Partner | 17 May 2021 | 5 yrs 5 mo | Leiutis Pharmaceuticals Llp |
Financials of Leiutis
Figures of Leiutis Pharmaceuticals Llp, the primary company behind Leiutis, for FY 2025. Revenue was ₹52.13 Cr (-39% year on year). Net profit was ₹16.73 Cr (32% margin). EBITDA was ₹28.53 Cr (55% margin). Revenue has grown at a compounded annual rate of -18% over three years.
- ₹52.13 CrRevenue · FY 2025 · -39% YoY
- ₹16.73 CrNet profit · 32% margin
- ₹28.53 CrEBITDA · 55% margin
- 72Employees (provident fund records)
- -18%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Leiutis Pharmaceuticals Llp are on its company page.
Detailed financial statements for Leiutis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Leiutis
Complete news archive for Leiutis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Leiutis
Leiutis was founded in 2012.
Leiutis is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Leiutis has 66 employees.
The primary company behind Leiutis, Leiutis Pharmaceuticals Llp, reported revenue of ₹52.13 Cr for FY 2025, down 39% year on year.
Leiutis is a pharmaceutical product innovation company specializing in nanotherapeutics to foster patient wellbeing through research and global partnerships. They focus on commercializing products in areas like pain management, supportive care, CNS disorders, and immunomodulators. Operating from Hyderabad, India, they engage in alliance partnerships for successful commercialization, emphasizing innovative treatments without promotional claims.
Leiutis offers Nanotherapeutics for Pain Management, Nanotherapeutics for Supportive Care, Nanotherapeutics for CNS Disorders, and Nanotherapeutics for Immunomodulators.
Leiutis operates through Leiutis Pharmaceuticals Llp.
The legal entities of Leiutis currently have 6 directors, including Manikreddy Pullagurla, Harcharan Singh, Chandra Shekhar Kocherlakota and others.